NO20091266L - Fremgangsmåter for administrering av langvarige hypoglykemiske midler - Google Patents

Fremgangsmåter for administrering av langvarige hypoglykemiske midler

Info

Publication number
NO20091266L
NO20091266L NO20091266A NO20091266A NO20091266L NO 20091266 L NO20091266 L NO 20091266L NO 20091266 A NO20091266 A NO 20091266A NO 20091266 A NO20091266 A NO 20091266A NO 20091266 L NO20091266 L NO 20091266L
Authority
NO
Norway
Prior art keywords
term
methods
hypoglycaemic agents
administering long
administering
Prior art date
Application number
NO20091266A
Other languages
English (en)
Inventor
Mark A Bush
Jessica E Matthews
Susan E Walker
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of NO20091266L publication Critical patent/NO20091266L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
NO20091266A 2006-09-13 2009-03-26 Fremgangsmåter for administrering av langvarige hypoglykemiske midler NO20091266L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82547206P 2006-09-13 2006-09-13
US86839106P 2006-12-04 2006-12-04
PCT/US2007/078226 WO2008033888A2 (en) 2006-09-13 2007-09-12 Methods for administering long-lasting hypoglycemic agents

Publications (1)

Publication Number Publication Date
NO20091266L true NO20091266L (no) 2009-06-09

Family

ID=39184534

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20091266A NO20091266L (no) 2006-09-13 2009-03-26 Fremgangsmåter for administrering av langvarige hypoglykemiske midler

Country Status (25)

Country Link
US (3) US8338369B2 (no)
EP (1) EP2073834B1 (no)
JP (2) JP5524620B2 (no)
KR (1) KR101472601B1 (no)
CN (1) CN103705911A (no)
AR (1) AR062775A1 (no)
AU (1) AU2007296499C1 (no)
BR (1) BRPI0716765A8 (no)
CA (1) CA2662622C (no)
CL (1) CL2007002634A1 (no)
CR (1) CR10684A (no)
EA (1) EA017159B1 (no)
ES (1) ES2442869T3 (no)
IL (1) IL197448A (no)
JO (1) JO2945B1 (no)
MA (1) MA30768B1 (no)
MX (1) MX2009002863A (no)
MY (1) MY149911A (no)
NO (1) NO20091266L (no)
NZ (1) NZ575419A (no)
PE (2) PE20080840A1 (no)
SG (2) SG10201501749WA (no)
TW (1) TWI430806B (no)
WO (1) WO2008033888A2 (no)
ZA (1) ZA200901548B (no)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009514900A (ja) 2005-11-04 2009-04-09 スミスクライン・ビーチャム・コーポレイション 血糖降下剤の投与方法
HUE031900T2 (en) 2008-12-10 2017-08-28 Glaxosmithkline Llc Pharmaceutical compositions containing Albiglutide
WO2011140176A1 (en) * 2010-05-04 2011-11-10 Glaxosmithkline Llc Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
RU2600440C3 (ru) 2010-12-16 2021-12-10 Ново Нордиск А/С Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
CN106117344B (zh) 2011-04-12 2020-11-03 诺沃—诺迪斯克有限公司 双酰化glp-1衍生物
ES2715308T3 (es) 2012-03-22 2019-06-03 Novo Nordisk As Composiciones que comprenden un agente de suministro y su preparación
US10933120B2 (en) 2012-03-22 2021-03-02 Novo Nordisk A/S Compositions of GLP-1 peptides and preparation thereof
EP2863895B1 (en) 2012-06-20 2021-04-14 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
BR112015026325A2 (pt) 2013-05-02 2017-07-25 Novo Nordisk As dosagem oral de compostos glp-1
TWI638831B (zh) 2013-05-28 2018-10-21 日商武田藥品工業股份有限公司 胜肽化合物
WO2017204219A1 (ja) 2016-05-24 2017-11-30 武田薬品工業株式会社 ペプチド化合物
EP3746111B1 (en) 2018-02-02 2023-07-19 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
AR125086A1 (es) * 2021-03-23 2023-06-07 Lilly Co Eli Composiciones que contienen análogos de incretina y usos de estas

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
CA2262647C (en) 1996-08-08 2007-12-04 Amylin Pharmaceuticals, Inc. Methods for regulating gastrointestinal motility
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
CN1314818A (zh) * 1998-08-28 2001-09-26 伊莱利利公司 服用促胰岛素肽的方法
US6329336B1 (en) * 1999-05-17 2001-12-11 Conjuchem, Inc. Long lasting insulinotropic peptides
US6395767B2 (en) * 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
WO2002046227A2 (en) 2000-12-07 2002-06-13 Eli Lilly And Company Glp-1 fusion proteins
AU2002239384B2 (en) * 2000-12-13 2007-01-11 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
WO2002098348A2 (en) * 2001-06-01 2002-12-12 Eli Lilly And Company Glp-1 formulations with protracted time action
IL160493A0 (en) * 2001-08-23 2004-07-25 Lilly Co Eli Glucagon-like peptide-1 analogs
AR036711A1 (es) 2001-10-05 2004-09-29 Bayer Corp Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
KR20040054729A (ko) 2001-10-18 2004-06-25 브리스톨-마이어스 스큅 컴퍼니 인간 글루카곤-유사-펩티드-1 모방체, 및 당뇨병 및 이와관련된 증상의 치료에 있어서 이의 용도
AU2002364587A1 (en) 2001-12-21 2003-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
CA2471363C (en) * 2001-12-21 2014-02-11 Human Genome Sciences, Inc. Albumin fusion proteins
AU2003200839B2 (en) * 2002-01-08 2008-12-11 Eli Lilly And Company Extended glucagon-like peptide-1 analogs
CA2513213C (en) 2003-01-22 2013-07-30 Human Genome Sciences, Inc. Albumin fusion proteins
WO2005047297A1 (en) * 2003-11-12 2005-05-26 Phenomix Corporation Heterocyclic boronic acid compounds
WO2005068191A1 (ja) * 2004-01-13 2005-07-28 Asahi Glass Company, Limited 多層積層体
MXPA06009072A (es) 2004-02-09 2007-03-29 Human Genome Sciences Inc Proteinas de fusion de albumina.
CN1950078A (zh) * 2004-06-11 2007-04-18 诺和诺德公司 使用glp－1激动剂抵抗药物诱发的肥胖
JP2009514900A (ja) * 2005-11-04 2009-04-09 スミスクライン・ビーチャム・コーポレイション 血糖降下剤の投与方法
WO2007139589A1 (en) 2006-05-26 2007-12-06 Bristol-Myers Squibb Company Sustained release glp-1 receptor modulators

Also Published As

Publication number Publication date
AR062775A1 (es) 2008-12-03
EP2073834A4 (en) 2010-11-03
MA30768B1 (fr) 2009-10-01
CN103705911A (zh) 2014-04-09
MY149911A (en) 2013-10-31
CR10684A (es) 2009-04-28
AU2007296499B2 (en) 2013-05-02
EP2073834A2 (en) 2009-07-01
BRPI0716765A8 (pt) 2017-02-21
ZA200901548B (en) 2010-02-24
US20100009910A1 (en) 2010-01-14
MX2009002863A (es) 2009-03-30
US20130005652A1 (en) 2013-01-03
JO2945B1 (en) 2016-03-15
PE20121528A1 (es) 2012-12-12
EP2073834B1 (en) 2013-10-23
SG10201501749WA (en) 2015-05-28
CA2662622C (en) 2017-01-17
BRPI0716765A2 (pt) 2013-09-24
KR20090059155A (ko) 2009-06-10
US8338369B2 (en) 2012-12-25
PE20080840A1 (es) 2008-08-27
WO2008033888A3 (en) 2008-10-16
SG174770A1 (en) 2011-10-28
US20140066371A1 (en) 2014-03-06
CA2662622A1 (en) 2008-03-20
ES2442869T3 (es) 2014-02-14
NZ575419A (en) 2011-11-25
IL197448A0 (en) 2011-08-01
EA017159B1 (ru) 2012-10-30
TW200824706A (en) 2008-06-16
TWI430806B (zh) 2014-03-21
CL2007002634A1 (es) 2008-05-16
AU2007296499C1 (en) 2013-09-12
EA200970274A1 (ru) 2009-08-28
WO2008033888A2 (en) 2008-03-20
JP5524620B2 (ja) 2014-06-18
KR101472601B1 (ko) 2014-12-15
JP2010503697A (ja) 2010-02-04
JP5753924B2 (ja) 2015-07-22
IL197448A (en) 2013-06-27
JP2014148524A (ja) 2014-08-21
AU2007296499A1 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
NO20091266L (no) Fremgangsmåter for administrering av langvarige hypoglykemiske midler
LTPA2016032I1 (lt) Hipoglikeminių agentų skyrimo būdai
CY2014012I2 (el) Χορηγηση αναστολεων διπεπτιδυλοπεπτιδασης
DOP2007000084A (es) Derivados de dihidropirazolopirimidinona
LTPA2016005I1 (lt) Anti-il-5 antikūnų skyrimo būdai
DK2474321T3 (da) Sammensætninger til behandling af collagenmedierede sygdomme
CR10562A (es) Nuevos derivados de piridazina
BRPI0715712A2 (pt) Composição farmacêutica
DK3421471T3 (da) Purin- og deazapurinderivater som farmaceutiske forbindelser
DK1874781T3 (da) Dihydrothienopyrimidiner til behandling af inflammatoriske sygdomme
DK2073795T3 (da) Misbrugssikret lægemiddelformulation
DK2041139T3 (da) Farmaceutiske forbindelser
ATE531720T1 (de) Aza-benzofuranylverbindungen und anwendungsverfahren dafür
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
DK1940467T3 (da) Lægemiddelsammensætning med langvarig frigivelse
BRPI0719393A2 (pt) Composição farmacêutica
DK1984009T3 (da) Farmaceutiske sammensætninger med forbedret stabilitet
DK1940839T3 (da) Pyridopyrimidione Inhibitors of P13Ka
ITVR20060060A1 (it) Struttura di seggiolone
FI20065757A (fi) Beta-laktamaasin käyttö
BRPI0716445A2 (pt) composiÇço farmacÊutica
BRPI0720234A2 (pt) Composição farmacêutica
DK2035369T3 (da) Terapeutiske
NO20055643D0 (no) Preparation of lodixanol
DK2285808T3 (da) Spiroindolderivater til behandling af parasitsygdomme

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application